DexCom (DXCM) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.73
- Estimate
- $0.67
- Surprise
- +8.3%
- Revenue (period 2026-09-30)
- $1.34B
- Score today
- 6.7/10
Revenue source: xbrl.
How the report landed
DexCom (DXCM) beat the $0.67 estimate with adjusted EPS of $0.73 — a clear 8.3% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates DXCM Buy (Wait) at 6.7/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +8.3% surprise compares with a +11.7% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.5 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: CGM systems
- Concentration risk — Supplier: single- or sole-source suppliers
- Thin upside margin: 8.3%
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $79.93
- Entry target
- $77.35
- Price target
- $86.57
- Stop
- $74.22
- Upside to target
- +8.3%
- Reward-to-risk
- 1.3:1
The stock trades at 31.7× trailing but 25.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-30 — shown for context, not personalized investment advice.
DXCM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $30.16B
- P/E (fwd)
- 25.6
- P/E (ttm)
- 31.7
- 52-week range
- $54.11–$92.59
- Off 52-week high
- 13.7%
- RSI (14)
- 40
- Volume vs avg
- 1.33×
- Score today
- 6.7/10